Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R T D'Aquila

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Annals of Internal Medicine|June 15, 1996
Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 InvestigatorsR T D'Aquila, M D Hughes, V A Johnson, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1993
Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working GroupA J Japour, D L Mayers, V A Johnson, et al.
Antimicrobial Agents and Chemotherapy|July 1, 1993
pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivoJ J Eron, Y K Chow, A M Caliendo, et al.
The Journal of Infectious Diseases|May 1, 1995
Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working GroupA J Japour, S Welles, R T D'Aquila, et al.
Nature|October 12, 2000
Immune control of HIV-1 after early treatment of acute infectionE S Rosenberg, M Altfeld, S H Poon, et al.
The Journal of Infectious Diseases|April 27, 2000
The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850)J J Eron, L M Smeaton, S A Fiscus, et al.
Annals of Internal Medicine|March 15, 1995
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working GroupR T D'Aquila, V A Johnson, S L Welles, et al.
Annals of Internal Medicine|June 15, 1997
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy TeamM D Hughes, V A Johnson, M S Hirsch, et al.
Journal of Virology|June 11, 1999
Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infectionC M Hay, D J Ruhl, N O Basgoz, et al.
The Journal of Infectious Diseases|February 22, 2001
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373R M Gulick, L M Smeaton, R T D'Aquila, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Annals of Internal Medicine|June 15, 1996
Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 InvestigatorsR T D'Aquila, M D Hughes, V A Johnson, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1993
Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working GroupA J Japour, D L Mayers, V A Johnson, et al.
Antimicrobial Agents and Chemotherapy|July 1, 1993
pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivoJ J Eron, Y K Chow, A M Caliendo, et al.
The Journal of Infectious Diseases|May 1, 1995
Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working GroupA J Japour, S Welles, R T D'Aquila, et al.
Nature|October 12, 2000
Immune control of HIV-1 after early treatment of acute infectionE S Rosenberg, M Altfeld, S H Poon, et al.
The Journal of Infectious Diseases|April 27, 2000
The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850)J J Eron, L M Smeaton, S A Fiscus, et al.
Annals of Internal Medicine|March 15, 1995
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working GroupR T D'Aquila, V A Johnson, S L Welles, et al.
Annals of Internal Medicine|June 15, 1997
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy TeamM D Hughes, V A Johnson, M S Hirsch, et al.
Journal of Virology|June 11, 1999
Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infectionC M Hay, D J Ruhl, N O Basgoz, et al.
The Journal of Infectious Diseases|February 22, 2001
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373R M Gulick, L M Smeaton, R T D'Aquila, et al.
Pageof 7